新辅助化疗方案治疗局部晚期乳腺癌60例的疗效分析

目的:探讨新辅助化疗(TAC方案)治疗局部晚期乳腺癌的临床疗效和毒副作用。方法:回顾性分析60例术前接受TAC新辅助化疗的局部晚期乳腺癌患者的临床资料。TAC方案:多西紫杉醇静脉滴注(75 mg·m-2,d 1);表阿霉素静脉滴注(75 mg·m-2,d 1);环磷酰胺静脉滴注(600 mg·m-2,d 1)。共进行为期4个疗程的治疗,1个疗程为21 d。结束后对患者化疗疗效以及毒副作用进行评定。结果:新辅助化疗(TAC方案)在LABC治疗中总有效率(cCR+cPR)为81.6%(49/60),其中临床完全缓解率(cCR)为18.3%(11/60),临床部分缓解率(cPR)为63.3%(38/60),病理完全缓解率(pCR)为10.0%(10/60)。主要的毒副反应以白细胞、中性白细胞减少为主,脱发和胃肠道反应,无败血症和死亡病例。结论:新辅助化疗(TAC方案)对局部晚期乳腺癌有较高缓解率和降期效果,安全性较好,毒性可控。

Efficacy analysis of treatment of locally advanced breast cancer with neoadjuvant chemotherapy

Objective:To evaluate the efficacy and toxicity of TAC regimen as neoadjuvant chemotherapy in the treatment of locally advanced breast cancer(LABC).Methods:The clinical data of 60 LABC patients underwent preoperative TAC treatment was retrospectively analyzed.TAC regimen(docetaxel,75mg·m-2,d1;epirubicin,75mg·m-2,d1;cyclophosphamide,600mg·m-2,d1) was administered every 21 days for 4 cycles.The efficacy and toxicity of the treatment were analyzed.Results:The efficacy rate(cCR+cPR) was 81.6%(49/60),cCR rate was 18.3%(11/60),cPR rate was 63.3%(38/60),and pCR rate was 10.0%(10/60).The most common toxicities were leukopenia,alopecia,nausea and vomiting.There was no serious septicemia and deaths.Conclusion:TAC regimen is a very effective and well-tolerated regimen as neoadjuvant chemotherapy for locally advanced breast cancer.